The company faces securities fraud investigation for allegedly misrepresenting clinical trial data as 'positive' while concealing serious safety concerns (anaphylaxis in patients). Stock declined 33.66% and 12.57% on two separate announcements, indicating investor loss of confidence and potential regulatory/legal jeopardy.
The company successfully upsized its public offering to $100 million, demonstrating investor confidence and providing substantial capital to advance its lead drug candidate nomlabofusp for Friedreich's ataxia treatment and support R&D operations.
Articles that tag LRMR but are mainly about other companies.
Articles and sentiment ratings from Massive / Polygon. Sentiment is the provider's model rating for this company, not Gainbot's view.
Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology
